You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,974,793


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,974,793
Title: Method for treating primary hyperparathyroid disorders
Abstract:A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.
Inventor(s): Donovan; Stephen (Capistrano Beach, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:09/971,869
Patent Claims:1. A method for treating a primary hyperparathyroid disorder, the method comprising the step of administration of a Clostridial neurotoxin to a sympathetic ganglion which innervates a parathyroid gland of a patient, thereby treating a primary hyperparathyroid disorder.

2. The method of claim 1, wherein the Clostridial neurotoxin is administered in an amount of between 10.sup.-3 U/kg and 35 U/kg.

3. The method of claim 1, wherein the Clostridial neurotoxin is a botulinum toxin.

4. The method of claim 3, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G.

5. The method of claim 3, wherein the neurotoxin is botulinum toxin type A.

6. A method for treating a primary hyperparathyroid disorder, the method comprising the step of administration of a therapeutically effective amount of a botulinum toxin to sympathetic ganglion which innervates a parathyroid gland of a patient, thereby treating a primary hyperparathyroid disorder.

7. The method of claim 6, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G.

8. A method for treating primary hyperparathyroidism, the method comprising the step of local administration to a sympathetic ganglion which innervates a parathyroid hormone (PTH) secreting parathyroid cell of a therapeutically effective amount of a botulinum toxin, thereby reducing an excessive parathyroid hormone secretion from the parathyroid cell and treating primary hyperparathyroidism.

9. The method of claim 8, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G.

10. The method of claim 1, wherein the sympathetic ganglion is a cervical ganglion.

11. The method of claim 6, wherein the sympathetic ganglion is a cervical ganglion.

12. The method of claim 8, wherein the sympathetic ganglion is a cervical ganglion.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.